test

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Conditions

Recurrent Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IV Melanoma

What is the purpose of this trial?

This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Monoclonal antibodies, such as ipilimumab, may interfere with the ability of tumor cells to grow and spread. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. It is not yet known whether ipilimumab is more effective than interferon alfa-2b in treating patients with melanoma.



Participation Guidelines

Age:
12 Years - N/A
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Cancer Institute (NCI)
Dates:
May 2011
Last Updated:
November 7, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01274338